Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Front Endocrinol (Lausanne). 2022 Apr 27:13:899616. doi: 10.3389/fendo.2022.899616. eCollection 2022.

¹ Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy.
² Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, United States.
³ Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, Netherlands.
⁴ Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Miami, Miami, FL, United States.
⁵ Department of Endocrinology, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, Aurora, CO, United States.
⁶ Allegheny Neuroendocrinology Center, Allegheny General Hospital, Pittsburgh, PA, United States.
⁷ Methodist Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States.
⁸ Department of Clinical and Biological Sciences, Internal Medicine 1 - San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.
⁹ Trialwise, Inc, Houston, TX, United States.
¹⁰ Corcept Therapeutics, Menlo Park, CA, United States.

Abstract

[This corrects the article DOI: 10.3389/fendo.2021.662865.].

Keywords: Cushing syndrome; clinical trial; cortisol; glucocorticoid; hypercortisolism; hyperglycemia; hypertension; relacorilant.